| abstract |
(57) Summary The present invention relates to a pharmacologically acceptable composition for suppressing or treating hemorrhagic shock in mammals. The composition comprises a KATP inhibitor and a pharmacologically acceptable carrier, the KATP inhibitor being present in an amount sufficient to inhibit or treat hemorrhagic shock in a mammal. The invention also relates to a method for inhibiting or treating hemorrhagic shock in a mammal. The method comprises the step of administering to the mammal a KATP channel inhibitor in an amount sufficient to inhibit or treat the hemorrhagic shock. In one preferred embodiment of the invention, the KATP channel inhibitor is a sulfonylurea, guanidine, phenothiazine, imidazoline, TMB-8 (8-N, N-diethylamino) octyl-3,4,5-trimethoxy. It is selected from the group consisting of benzoate, 2,3-butanedione monooxime, disopyramide, glyquidone, chlorpromazine, AMP-NPP, flecainide, MS-551, and combinations thereof. |